GANXGain TherapeuticsGANX info
$1.50info1.01%24h
Global rank29105
Market cap$24.22M
Change 7d-
YTD Performance-54.70%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Gain Therapeutics (GANX) Stock Overview

    Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

    GANX Stock Information

    Symbol
    GANX
    Address
    4800 Montgomery LaneBethesda, MD 20814United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.gaintherapeutics.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    301 500 1556

    Gain Therapeutics (GANX) Price Chart

    -
    Value:-

    Gain Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.50
    N/A
    Market Cap
    $24.22M
    N/A
    Shares Outstanding
    16.20M
    N/A
    Employees
    28.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org